Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012 (2012), Article ID 404581, 11 pages
http://dx.doi.org/10.1155/2012/404581
Review Article

Oncolytic Viruses in the Treatment of Bladder Cancer

1Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada T6G 2E1
2Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada T6G 2B7

Received 15 April 2012; Accepted 5 June 2012

Academic Editor: Nan-Haw Chow

Copyright © 2012 Kyle G. Potts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [6 citations]

The following is the list of published articles that have cited the current article.

  • Michelle Cronin, Fabrice Le Boeuf, Carola Murphy, Dominic G Roy, Theresa Falls, John C Bell, and Mark Tangney, “Bacterial-Mediated Knockdown of Tumor Resistance to an Oncolytic Virus Enhances Therapy,” Molecular Therapy, 2014. View at Publisher · View at Google Scholar
  • P.S. Holm, M. Retz, J.E. Gschwend, and R. Nawroth, “YB-1-basierte Virotherapie,” Der Urologe, 2015. View at Publisher · View at Google Scholar
  • Zahid Delwar, Kaixin Zhang, Paul S. Rennie, and William Jia, “Oncolytic virotherapy for urological cancers,” Nature Reviews Urology, 2016. View at Publisher · View at Google Scholar
  • Piyush K. Agarwal, Akhil Muthigi, Arvin K. George, and Sam J. Brancato, “Novel immunotherapeutic approaches to the treatment of urothelial carcinoma,” Therapeutic Advances in Urology, vol. 8, no. 3, pp. 203–214, 2016. View at Publisher · View at Google Scholar
  • Kyle G. Potts, Chad R. Irwin, Nicole A. Favis, Desmond B. Pink, Krista M. Vincent, John D. Lewis, Ronald B. Moore, Mary M. Hitt, and David H. Evans, “Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models,” EMBO Molecular Medicine, vol. 9, no. 5, pp. 638–654, 2017. View at Publisher · View at Google Scholar
  • Satoru Taguchi, Hiroshi Fukuhara, Yukio Homma, and Tomoki Todo, “Current status of clinical trials assessing oncolytic virus therapy for urological cancers,” International Journal of Urology, 2017. View at Publisher · View at Google Scholar